| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 to be presented during an investor webcast on November 9, 2026 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts |
| 31 Jul 2026 |
Form 4: Campbell David Alan, Director
Gave 123,840 shares as a gift |
| 28 Jul 2026 | SCHEDULE 13G/A |
| 10 Jul 2026 |
Form 4: Campbell David Alan, Director
Received 7,000 shares by exercise or conversion ($29.5K) |
| 23 Jun 2026 |
8-K: Other Events
On June 23, 2026, William Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. (the "Company") under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Co... |
| 12 Jun 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others
Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Simson Jake, Director
Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Hernday Natasha, Director
Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Dobmeier Eric, Director
Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy) |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Janux Therapeutics, Inc. (the “Company”) held the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 17, 2026, the record date for the Annual Meeting, 60,961,546 shares of common stock wer... |
| 12 Jun 2026 |
Form 4: Kung Winston, Director
Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Capps Vickie L, Director
Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Barrett Ronald W, Director
Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy) |
| 04 Jun 2026 |
Form 4: Doyle Janeen Noel, Chief Corp. & Bus. Dev. Ofcr
Sold 4,059 shares ($56.9K) |
Loading...